These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12088081)

  • 1. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid.
    Verrotti A; Basciani F; De Simone M; Trotta D; Morgese G; Chiarelli F
    J Child Neurol; 2002 Apr; 17(4):265-8. PubMed ID: 12088081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid.
    Verrotti A; Basciani F; Morresi S; de Martino M; Morgese G; Chiarelli F
    Neurology; 1999 Jul; 53(1):230-2. PubMed ID: 10408570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of ghrelin in weight gain and growth in epileptic children using valproate.
    Gungor S; Yücel G; Akinci A; Tabel Y; Ozerol IH; Yologlu S
    J Child Neurol; 2007 Dec; 22(12):1384-8. PubMed ID: 18174556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
    Verrotti A; D'Egidio C; Mohn A; Coppola G; Chiarelli F
    Obes Rev; 2011 May; 12(5):e32-43. PubMed ID: 20880119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate.
    Aydin K; Serdaroglu A; Okuyaz C; Bideci A; Gucuyener K
    J Child Neurol; 2005 Oct; 20(10):848-51. PubMed ID: 16417885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and endocrine effects of valproic acid chronic treatment.
    Belcastro V; D'Egidio C; Striano P; Verrotti A
    Epilepsy Res; 2013 Nov; 107(1-2):1-8. PubMed ID: 24076030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy.
    Luef G; Abraham I; Hoppichler F; Trinka E; Unterberger I; Bauer G; Lechleitner M
    Metabolism; 2002 Oct; 51(10):1274-8. PubMed ID: 12370846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate-induced insulin resistance and obesity in children.
    Verrotti A; la Torre R; Trotta D; Mohn A; Chiarelli F
    Horm Res; 2009; 71(3):125-31. PubMed ID: 19188736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study.
    Sidhu HS; Srinivas R; Sadhotra A
    Seizure; 2017 May; 48():15-21. PubMed ID: 28365440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain.
    Hamed SA; Fida NM; Hamed EA
    Eur J Paediatr Neurol; 2009 May; 13(3):261-8. PubMed ID: 18586538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy.
    Kanemura H; Sano F; Maeda Y; Sugita K; Aihara M
    Seizure; 2012 Sep; 21(7):496-500. PubMed ID: 22694920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic alterations during valproic acid treatment: a prospective study.
    Abaci A; Saygi M; Yis U; Demir K; Dirik E; Bober E
    Pediatr Neurol; 2009 Dec; 41(6):435-9. PubMed ID: 19931165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
    Pylvänen V; Pakarinen A; Knip M; Isojärvi J
    Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy.
    Grosso S; Mostardini R; Piccini B; Balestri P
    Ann Pharmacother; 2009 Jan; 43(1):45-50. PubMed ID: 19066323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate.
    Verrotti A; Greco R; Latini G; De Simone M; Chiarelli F
    Neuroendocrinology; 2004 Mar; 79(3):157-62. PubMed ID: 15103229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproate-induced insulin resistance in prepubertal girls with epilepsy.
    Tan H; Orbak Z; Kantarci M; Koçak N; Karaca L
    J Pediatr Endocrinol Metab; 2005 Oct; 18(10):985-9. PubMed ID: 16355811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin and visfatin concentrations in children treated with valproic acid.
    Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Ernst B; Hoppichler F; Karall D; Ebenbichler CF; Rostasy K; Luef G
    Epilepsia; 2008 Feb; 49(2):353-7. PubMed ID: 18070089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate-associated reproductive hormone abnormalities: do bipolar men have the same risk as epileptic men?
    Aldemir E; Akdeniz F; Altay AB; Arıcı Ş; Umul M; Aydın HH; Çelebisoy M; Vahip S
    Turk Psikiyatri Derg; 2012; 23(4):223-7. PubMed ID: 23225122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Insulin resistance in epileptic patients during treatment of valproic acid].
    Ding MP; Bao YY; Chen Z; Liu ZR; Xu LL
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 May; 33(3):216-8. PubMed ID: 15179681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.